Abstract
Amprenavir (APV) has been shown to be effective in naive or treatment-experienced HIV-1 infected patients. However, the safety and efficacy of the APV 600 mg/ritonavir (RTV) 100 mg twice a day (bid) combination, the usually recommended dosage for boosted APV, have been less well studied. We assessed the predictive factors associated with virological success of APV/RTV-based regimens. Patients in the PharmAdapt study receiving an APV/RTV-containing regimen were included in the study. The predictivity of covariates on virological response at 4 months was analysed according to the data analysis plan. We processed logistic regression using bootstrapping to allow several covariates in the models. Forty patients received an APV/RTV-containing regimen, 38 of whom were male (95%). Risk factors were heterosexual contacts (four patients; 10%), homosexual contacts (31 patients; 78%), and intravenous drug use (four patients; 10%). Twenty-seven per cent of patients were Centers for Disease Control and Prevention Classification System (CDC) stage A, 38% were stage B and 35% were stage C. The median baseline CD4 count was 313 cells/microL [interquartile range (IQR) 211, 414], and the median baseline viral load was 4.4 log(10) HIV-1 RNA copies...Continue Reading
References
Feb 10, 1995·Journal of Chromatography. a·E WoolfB Matuszewski
May 3, 2000·Lancet·J Mellors, J Montaner
Jun 27, 2000·Clinical Therapeutics·H B FungR Hameed
Oct 19, 2000·Antimicrobial Agents and Chemotherapy·B SchmidtH Walter
Apr 11, 2001·Clinical Therapeutics·T ScottL Pedneault
Jun 16, 2001·AIDS·B M SadlerD S Stein
Jan 18, 2002·Antimicrobial Agents and Chemotherapy·Xavier DuvalJean-Louis Vilde
Jan 31, 2002·The Annals of Pharmacotherapy·Brian M Sadler, Daniel S Stein
Feb 9, 2002·AIDS·Judith FalloonUNKNOWN CNA2007 Study Team
Apr 20, 2002·AIDS·Jean-Luc MeynardUNKNOWN Narval Trial Group
Apr 27, 2002·HIV Clinical Trials·Cédric ArvieuxChristian Michelet
Jul 30, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Michael P DubéThomas A Buchanan
Sep 28, 2002·AIDS·Asunción CostaJosé R Costa
Nov 21, 2002·AIDS·Philippe ClevenberghPierre Dellamonica
Dec 25, 2002·Antimicrobial Agents and Chemotherapy·Cecile GoujardAnne-Marie Taburet
Jan 25, 2003·Antimicrobial Agents and Chemotherapy·Anne-Geneviève MarcelinUNKNOWN Genophar Study Group
Jun 24, 2003·AIDS·Tanja SchnellHauke Walter
Aug 5, 2003·Antiviral Research·Robert J Visalli, Marja van Zeijl
Sep 5, 2003·International Journal of Clinical Oncology·William J Gradishar, Ruth M O'Regan
Jan 7, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Amalia Rodriguez-FrenchPaul G Wannamaker
Mar 10, 2004·AIDS Patient Care and STDs·Luisa ValerVincent Soriano
Jul 25, 2006·Clinical Therapeutics·Joseph C GatheJane Yeo
Citations
Jan 24, 2009·AIDS·Monica GandhiUNKNOWN Women's Interagency HIV Study (WIHS)
Feb 21, 2008·Antimicrobial Agents and Chemotherapy·Aurélie Barrail-TranUNKNOWN Puzzle-1 (ANRS 104) Study Group
Mar 25, 2009·Antimicrobial Agents and Chemotherapy·Joseph J EronUNKNOWN ACTG5126 Study Team
May 1, 2007·Current Opinion in HIV and AIDS·Saye H KhooDavid J Back
Aug 19, 2007·Scandinavian Journal of Infectious Diseases·Simona Di GiambenedettoAndrea De Luca
Jun 29, 2005·HIV Clinical Trials·Romina QuerciaFrançois Raffi
Mar 4, 2011·Journal of the International Association of Physicians in AIDS Care : JIAPAC·May Myat WinSomnuek Sungkanuparph